BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. The company is headquartered in Stockholm, Stockholm and currently employs 122 full-time employees. The company went IPO on 2017-10-12. The firm focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The firm owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The firm's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The firm also operates through SpineMedical AB.
BioArctic AB (publ) tiene un dividendo anual de 0.00 por acción, con un rendimiento del 0.00%. El dividendo se paga anualmente y la última fecha ex-dividendo fue May 10, 2019.
Rendimiento de dividendos
Dividendo anual
Fecha de ex-dividendos
0.00%
$0.00
May 10, 2019
Frecuencia de pago
Relación de pago
Anualmente
0.00%
Historial de dividendos
Fecha de ex-dividendos
Monto en efectivo
Fecha de Registro
Fecha de Pago
May 10, 2019
$1.50
May 13, 2019
May 16, 2019
Gráficos de dividendos
BRCTF Dividendos
BRCTF Crecimiento de Dividendos (YoY)
Follow-Up Questions
¿Cuál es el dividendo actual pagado por BioArctic AB (publ) y su dividendo anual?
¿Cuál es el ratio de pago de dividendos de BioArctic AB (publ)?
¿Cuál es la fecha ex-dividendo para BRCTF?
¿Con qué frecuencia paga dividendos BioArctic AB (publ)?